TY - JOUR
T1 - Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure
T2 - a randomised, controlled, multinational, open-label meta-trial
AU - Awake Prone Positioning Meta-Trial Group
AU - Ehrmann, Stephan
AU - Li, Jie
AU - Ibarra-Estrada, Miguel
AU - Perez, Yonatan
AU - Pavlov, Ivan
AU - McNicholas, Bairbre
AU - Roca, Oriol
AU - Mirza, Sara
AU - Vines, David
AU - Garcia-Salcido, Roxana
AU - Aguirre-Avalos, Guadalupe
AU - Trump, Matthew W.
AU - Nay, Mai Anh
AU - Dellamonica, Jean
AU - Nseir, Saad
AU - Mogri, Idrees
AU - Cosgrave, David
AU - Jayaraman, Dev
AU - Masclans, Joan R.
AU - Laffey, John G.
AU - Tavernier, Elsa
AU - Elshafei, Ahmad A.
AU - Scott, Brady J.
AU - Weiss, Tyler
AU - Kaur, Ramandeep
AU - Harnois, Lauren J.
AU - Miller, Amanda
AU - Cerda, Flor
AU - Klein, Andrew
AU - Burd, Jacob R.
AU - Posa-Kearney, Kathleen
AU - Trump, Matthew
AU - Jackson, Julie
AU - Oetting, Trevor
AU - Greenwood, Mark
AU - Hazel, Lindsay
AU - Kingery, Lisa
AU - Morris, Lindsey
AU - Moon, Joon Yong
AU - Garnett, Julianne
AU - Jia, Shijing
AU - Nelson, Kristine
AU - Giacomini, Camilla
AU - Brennan, Aoife
AU - Judge, Conor
AU - Kernan, Maeve
AU - Kelly, Claire
AU - Ranjan, Ritika
AU - Casey, Siobhan
AU - O'Connell, Kevin
AU - Newell, Evelyn
AU - Gallagher, David
AU - Nichol, Alistair
AU - Curley, Ger
AU - Estrada, Miguel Ibarra
AU - García-Salcido, Roxana
AU - Vargas-Obieta, Alexandra
AU - Aguirre-Díaz, Sara A.
AU - Alcántar-Vallín, Luz
AU - Alvarado-Padilla, Montserrat
AU - Chávez-Peña, Quetzalcóatl
AU - López-Pulgarín, José A.
AU - Mijangos-Méndez, Julio C.
AU - Marín-Rosales, Miguel
AU - García-Alvarado, Jorge E.
AU - Baltazar-González, Oscar G.
AU - González-Guerrero, Maura C.
AU - Gutiérrez Ramírez, Paola G.
AU - Gilman, Sean
AU - Plamondon, Patrice
AU - Roy, Rachel
AU - Shahin, Jason
AU - Ragoshai, Raham
AU - Kaur, Aasmine
AU - Campisi, Josie
AU - Dahine, Joseph
AU - Perron, Stefanie
AU - Achouri, Slimane
AU - Racette, Ronald
AU - Kulenkamp, Anne
AU - Pacheco, Andrés
AU - García-de-Acilu, Marina
AU - Dot, Irene
AU - Bodet-Contentin, Laetitia
AU - Garot, Denis
AU - Mercier, Emmanuelle
AU - Salmon Gandonnière, Charlotte
AU - Morisseau, Marlène
AU - Jouan, Youenn
AU - Darwiche, Walid
AU - Legras, Annick
AU - Guillon, Antoine
AU - Dequin, Pierre François
AU - Tellier, Anne Charlotte
AU - Reignier, Jean
AU - Lascarrou, Jean Baptiste
AU - Seguin, Amélie
AU - Desmedt, Luc
AU - Canet, Emmanuel
AU - Guitton, Christophe
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12
Y1 - 2021/12
N2 - Background: Awake prone positioning has been reported to improve oxygenation for patients with COVID-19 in retrospective and observational studies, but whether it improves patient-centred outcomes is unknown. We aimed to evaluate the efficacy of awake prone positioning to prevent intubation or death in patients with severe COVID-19 in a large-scale randomised trial. Methods: In this prospective, a priori set up and defined, collaborative meta-trial of six randomised controlled open-label superiority trials, adults who required respiratory support with high-flow nasal cannula for acute hypoxaemic respiratory failure due to COVID-19 were randomly assigned to awake prone positioning or standard care. Hospitals from six countries were involved: Canada, France, Ireland, Mexico, USA, Spain. Patients or their care providers were not masked to allocated treatment. The primary composite outcome was treatment failure, defined as the proportion of patients intubated or dying within 28 days of enrolment. The six trials are registered with ClinicalTrials.gov, NCT04325906, NCT04347941, NCT04358939, NCT04395144, NCT04391140, and NCT04477655. Findings: Between April 2, 2020 and Jan 26, 2021, 1126 patients were enrolled and randomly assigned to awake prone positioning (n=567) or standard care (n=559). 1121 patients (excluding five who withdrew from the study) were included in the intention-to-treat analysis. Treatment failure occurred in 223 (40%) of 564 patients assigned to awake prone positioning and in 257 (46%) of 557 patients assigned to standard care (relative risk 0·86 [95% CI 0·75−0·98]). The hazard ratio (HR) for intubation was 0·75 (0·62−0·91), and the HR for mortality was 0·87 (0·68−1·11) with awake prone positioning compared with standard care within 28 days of enrolment. The incidence of prespecified adverse events was low and similar in both groups. Interpretation: Awake prone positioning of patients with hypoxaemic respiratory failure due to COVID-19 reduces the incidence of treatment failure and the need for intubation without any signal of harm. These results support routine awake prone positioning of patients with COVID-19 who require support with high-flow nasal cannula. Funding: Open AI inc, Rice Foundation, Projet Hospitalier de Recherche Clinique Interrégional, Appel d'Offre 2020, Groupement Interrégional de Recherche Clinique et d'Innovation Grand Ouest, Association pour la Promotion à Tours de la Réanimation Médicale, Fond de dotation du CHRU de Tours, Fisher & Paykel Healthcare Ltd.
AB - Background: Awake prone positioning has been reported to improve oxygenation for patients with COVID-19 in retrospective and observational studies, but whether it improves patient-centred outcomes is unknown. We aimed to evaluate the efficacy of awake prone positioning to prevent intubation or death in patients with severe COVID-19 in a large-scale randomised trial. Methods: In this prospective, a priori set up and defined, collaborative meta-trial of six randomised controlled open-label superiority trials, adults who required respiratory support with high-flow nasal cannula for acute hypoxaemic respiratory failure due to COVID-19 were randomly assigned to awake prone positioning or standard care. Hospitals from six countries were involved: Canada, France, Ireland, Mexico, USA, Spain. Patients or their care providers were not masked to allocated treatment. The primary composite outcome was treatment failure, defined as the proportion of patients intubated or dying within 28 days of enrolment. The six trials are registered with ClinicalTrials.gov, NCT04325906, NCT04347941, NCT04358939, NCT04395144, NCT04391140, and NCT04477655. Findings: Between April 2, 2020 and Jan 26, 2021, 1126 patients were enrolled and randomly assigned to awake prone positioning (n=567) or standard care (n=559). 1121 patients (excluding five who withdrew from the study) were included in the intention-to-treat analysis. Treatment failure occurred in 223 (40%) of 564 patients assigned to awake prone positioning and in 257 (46%) of 557 patients assigned to standard care (relative risk 0·86 [95% CI 0·75−0·98]). The hazard ratio (HR) for intubation was 0·75 (0·62−0·91), and the HR for mortality was 0·87 (0·68−1·11) with awake prone positioning compared with standard care within 28 days of enrolment. The incidence of prespecified adverse events was low and similar in both groups. Interpretation: Awake prone positioning of patients with hypoxaemic respiratory failure due to COVID-19 reduces the incidence of treatment failure and the need for intubation without any signal of harm. These results support routine awake prone positioning of patients with COVID-19 who require support with high-flow nasal cannula. Funding: Open AI inc, Rice Foundation, Projet Hospitalier de Recherche Clinique Interrégional, Appel d'Offre 2020, Groupement Interrégional de Recherche Clinique et d'Innovation Grand Ouest, Association pour la Promotion à Tours de la Réanimation Médicale, Fond de dotation du CHRU de Tours, Fisher & Paykel Healthcare Ltd.
UR - https://www.scopus.com/pages/publications/85122546297
U2 - 10.1016/S2213-2600(21)00356-8
DO - 10.1016/S2213-2600(21)00356-8
M3 - Article
C2 - 34425070
AN - SCOPUS:85122546297
SN - 2213-2600
VL - 9
SP - 1387
EP - 1395
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 12
ER -